Characteristics, treatment patterns, and biomarker testing of patients with advanced RET fusion-positive non-small cell lung cancer in a real-world multi-country observational study: a brief report
IntroductionApproximately 1−2% of non-small cell lung cancers (NSCLCs) are positive for rearranged during transfection (RET) gene fusions. The aim of this real-world multi-national study was to describe clinical characteristics, biomarker testing, and treatment patterns of patients with RET fusion-p...
Saved in:
Main Authors: | Urpo Kiiskinen, Grace Segall, Hollie Bailey, Cameron Forshaw, Tarun Puri |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2025-02-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2025.1470387/full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Mucocutaneous Adverse Events in Patients With Cancer Treated with the Highly Selective RET Kinase Inhibitor Selpercatinib (LOXO-292)
by: Rachel E. Reingold, MD, et al.
Published: (2025-03-01) -
Remarkable response to low dose of selpercatinib in a patient with RET-rearranged non-small cell lung cancer
by: Jun Sakakibara-Konishi, et al.
Published: (2025-01-01) -
Brief report: impact of consolidation durvalumab on unresectable non-small cell lung cancer with driver mutations
by: Jason C.S. Ho, et al.
Published: (2024-01-01) -
Oligopolios mixtos, fusiones y liberación comercial
by: José Méndez Naya
Published: (2009-01-01) -
Expanding perspectives on the relationship between statin potency and lipophilicity in Alzheimer's disease management
by: Yixiang Hu, et al.
Published: (2025-02-01)